Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bezlotoxumab in Fulminant Clostridioides Difficile Requiring Surgery
NCT03756454Phase 4Terminated
- Sponsor
- The Ohio State University
- Start
- Aug 2019
- Primary completion
- May 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bezlotoxumab in Clostridioides difficile infection (CDI) (2 arms), sponsored by The Ohio State University. Primary endpoint: Mortality at 30 days. Started Aug 2019; status: terminated.
02
Drugs
bezlotoxumab
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT03756454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03756454.